Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2020-06-16 Major Shareholding Noti…
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and contractual relationships (such as pledges) of major shareholders. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-06-16 Korean
장래사업ㆍ경영계획(공정공시)
Board/Management Information Classification · 95% confidence The document is a 'Future Business and Management Plan' (장래사업ㆍ경영 계획) filed by Samsung Pharmaceutical. It details a specific strategic initiative regarding a hotel business contract with Hyatt. Since this is a regulatory disclosure of a company's strategic business plan and does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2020-06-15 Korean
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Samsung Pharm Co., Ltd. for the period of 2020-01-01 to 2020-03-31. It contains detailed financial data, business descriptions, capital changes, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, but the report itself. Q1 2020
2020-05-15 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure relates to changes in capital structure and financial instruments, which falls under the 'Capital/Financing Update' category.
2020-05-14 Korean
사업보고서 (2019.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Samsung Pharm Co., Ltd. for the fiscal year 2019. It contains detailed financial statements, management discussions, capital structure, and governance information. This is the standard Korean regulatory filing equivalent to a 10-K annual report. The document length and content confirm it is the full report, not an announcement. FY 2019
2020-03-30 Korean
정기주주총회결과(제66기)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (정기주주총회결과). It details the approval of financial statements, dividend decisions, election of directors and auditors, and other resolutions passed during the meeting. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2020-03-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.